PP2A and GSK3 act as modifiers of FUS-ALS by modulating mitochondrial transport.
Ontology highlight
ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which currently lacks effective treatments. Mutations in the RNA-binding protein FUS are a common cause of familial ALS, accounting for around 4% of the cases. Understanding the mechanisms by which mutant FUS becomes toxic to neurons can provide insight into the pathogenesis of both familial and sporadic ALS. We have previously observed that overexpression of wild-type or ALS-mutant FUS in Drosophila motor neurons is toxic, which allowed us to screen for novel genetic modifiers of the disease. Using a genome-wide screening approach, we identified Protein Phosphatase 2A (PP2A) and Glycogen Synthase Kinase 3 (GSK3) as novel modifiers of FUS-ALS. Loss of function or pharmacological inhibition of either protein rescued FU
SUBMITTER: Tziortzouda P
PROVIDER: S-EPMC10873455 | biostudies-literature | 2024 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA